Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. China Isotope & Radiation Corporation
  6. Summary
    1763   CNE1000031F4

CHINA ISOTOPE & RADIATION CORPORATION

(1763)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
24.9 25.65 25.05 25.4 26.45 Last
270200 135400 152800 171600 174200 Volume
+2.05% +3.01% -2.34% +1.40% +4.13% Change
Estimated financial data (e)
Sales 2021 5 026 M 793 M 793 M
Net income 2021 349 M 55,1 M 55,1 M
Net Debt 2021 - - -
P/E ratio 2021 19,8x
Yield 2021 -
Sales 2022 6 103 M 963 M 963 M
Net income 2022 425 M 67,1 M 67,1 M
Net Debt 2022 - - -
P/E ratio 2022 16,2x
Yield 2022 -
Capitalization 6 887 M 1 087 M 1 087 M
Capi. / Sales 2021 1,37x
Capi. / Sales 2022 1,13x
Nbr of Employees 2 986
Free-Float -
More Financials
Company
China Isotope & Radiation Corporation is a China-based company principally engaged in the research, development, manufacture and sales of radiopharmaceuticals for the diagnosis and treatment of radiopharmaceuticals, as well as medical and industrial radioactive source products. The Company also provides radiation sterilization services. The Company is also involved in the design, manufacture and installation of Gama... 
Sector
Pharmaceuticals
Calendar
03/31Earnings Release
More about the company
Ratings of China Isotope & Radiation Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CHINA ISOTOPE & RADIATION CORPORATION
01/03China Isotope & Radiation Forming JV to Produce, Sell Isotope Products in China
MT
2021China Isotope & Radiation Corporation Enters into Investment Agreement Regarding the Es..
CI
2021China Isotope & Radiation Arm Delivers Lutetium Chloride Solution for R&D in China; Sha..
MT
2021CHINA ISOTOPE & RADIATION : Forms Health Service Joint Venture With German Radiopharmaceut..
MT
2021CHINA ISOTOPE & RADIATION : H1 Profit Soars 48.5%; Shares Slump 11%
MT
2021CHINA ISOTOPE & RADIATION : CIRC JV's Radiotherapy Products Bag 26 Licenses in China; Shar..
MT
2021CHINA ISOTOPE & RADIATION : Voluntary announcement
PU
2021CHINA ISOTOPE & RADIATION : Poll results of the annual general meeting and distribution of..
PU
2021China Isotope & Radiation Corporation Approves Final Dividend for the Year Ended Decemb..
CI
2021China Isotope & Radiation Corporation Proposes Final Dividend for the Year Ended Decemb..
CI
2021CHINA ISOTOPE & RADIATION : Voluntary announcement - entering into investment agreement wi..
PU
2021CHINA ISOTOPE & RADIATION : Proxy Form for the Annual General Meeting
PU
2021China Isotope & Radiation Corporation Proposes Final Dividend for the Year Ended Decemb..
CI
2021China Isotope & Radiation Corporation Proposes Dividend for the Year Ended December 31,..
CI
2021China Isotope & Radiation Corporation Reports Earnings Results for the Full Year Ended ..
CI
More news
News in other languages on CHINA ISOTOPE & RADIATION CORPORATION
01/03China Isotope & Radiation forme une coentreprise pour produire et vendre des produits i..
2021China Isotope & Radiation Corporation conclut un accord d'investissement concernant la ..
2021China Isotope & Radiation Arm livre une solution de chlorure de lutécium pour la R&D en..
2021China Isotope & Radiation forme une coentreprise de services de santé avec une entrepri..
2021Le bénéfice du premier semestre de China Isotope & Radiation grimpe de 48,5 % ; les act..
More news
Chart CHINA ISOTOPE & RADIATION CORPORATION
Duration : Period :
China Isotope & Radiation Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHINA ISOTOPE & RADIATION CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 26,45 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Suo Hui Wang General Manager & Executive Director
Yan Bin Meng Chairman
Qing Jun Zhang Chairman-Supervisory Board
Qing Liang Guo Independent Non-Executive Director
Yan Meng Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
CHINA ISOTOPE & RADIATION CORPORATION20.23%1 087
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356